Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077749 | 0.88 | NAMPT (0.53) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL2679342 | 0.82 | MMP1 (0.47) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL2679345 | 0.82 | MMP1 (0.47) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL10054825 | 0.82 | MMP1 (0.47) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL2679819 | 0.79 | SMN1; SMN2 (0.51) | KDM4ETRPV1TP53MAPTSMN1; SMN2 | |
| SCHEMBL10054824 | 0.79 | SMN1; SMN2 (0.51) | KDM4ETRPV1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2679821 | 0.79 | SMN1; SMN2 (0.51) | KDM4ETRPV1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2679606 | 0.76 | LMNA (0.49) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL2679114 | 0.76 | HDAC1 (0.50) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL10077696 | 0.76 | LMNA (0.49) | MMP1MMP2MMP9EGFRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | MMP1 2446/4885MMP2 2479/4885MMP9 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.